




Europäisches
Patentamt

European
Patent Office

Office européen
des brevets



4

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99104924.8

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE, 29/03/00
LA HAYE, LE



Eur päisches
Patentamt

European
Patent Office

Office eur péen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.: 99104924.8
Demande n°:

Anmeldetag:
Date of filing: 11/03/99
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
Société des Produits Nestlé S.A.
1800 Vevey
SWITZERLAND

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Lactic acid bacteria strains capable of preventing diarrhea

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:

A61K35/74, C12N1/20, A23L1/29, A23C9/152, // (C12N1/20, C12R1:225)

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

The title of the application reads as follows:
New lactic acid bacteria strains capable of preventing diarrhea



New lactic acid bacteria strains capable of preventing diarrhea

~~The present invention pertains to novel microorganisms of the family~~
Lactobacillaceae, especially to microorganisms of the genus Lactobacillus, that are useful in preventing or treating diarrhea. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestible support and to a composition containing the same.

Organisms that produce lactic acid as a major metabolic component have been known for a long time. These bacteria may be found in milk or in milk processing factories, respectively, living or decaying plants but also in the intestine of man and animals. These microorganisms, summarized under the term "lactic acid bacteria", represent a rather inhomogeneous group and comprise e.g. the genera Lactococcus, Lactobacillus, Streptococcus, Bifidobacterium, Pediococcus etc..

Lactic acid bacteria have been utilized as fermenting agents for the preservation of food taking benefit of a low pH and the action of fermentation products generated during the fermentative activity thereof to inhibit the growth of spoilage bacteria. To this end, lactic acid bacteria have been used for preparing a variety of different foodstuff such as cheese, yogurt and other fermented dairy products from milk.

Quite recently lactic acid bacteria have attracted a great deal of attention in that some strains have been found to exhibit valuable properties to man and animals upon ingestion. In particular, specific strains of Lactobacillus or Bifidobacterium have been found to be able to colonize the intestinal mucosa and to assist in the maintenance of the well-being of man and animal.

- 2 -

In this respect, EP 0 768 375 discloses specific strains of the genus *Bifidobacterium*, that are capable to become implanted in the intestinal flora and may adhere to intestinal cells. These *Bifidobacteria* are reported to assist in immunomodulation, being capable to competitively exclude adhesion of pathogenic bacteria to intestinal cells, thus assisting in the maintenance of the individual's health.

During the last few years research has also focused on the potential use of lactic acid bacteria as probiotic agents. Probiotics are considered to be viable microbial preparations which promote the individual's health by preserving the natural microflora in the intestine. A microbial preparation may be commonly accepted as a probiotic in case the effectual microbes thereof and their mode of action are known. Probiotics are deemed to attach to the intestine's mucosa, colonize the intestinal tract and likewise prevent attachment of harmful microorganisms thereon. A crucial prerequisite for their action resides in that they have to reach the gut's mucosa in a proper and viable form and do not get destroyed in the upper part of the gastrointestinal tract, especially by the influence of the low pH prevailing in the stomach.

In this respect, WO 97/00078 discloses a specific strain, termed *Lactobacillus* GG (ATCC 53103), as such a probiotic. The microorganism is particularly employed in a method of preventing or treating food induced hypersensitivity reactions in that it is administered to a recipient together with a food material that has been subjected to a hydrolysis treatment with pepsin and/or trypsin. The *Lactobacillus* strain selected is described as exhibiting adhesive and colonizing properties and showing a protease enzyme system, so that the protein material contained in the foodstuff to be administered is further hydrolysed by means of proteases secreted by the specific *Lactobacillus* strain. The method discussed in this document shall eventually result in the uptake of protein material by the gut that does not show a substantial amount of allergenic material anymore.

- 3 -

Further, in EP 0 577 903 reference is made to the use of such lactic acid bacteria having the ability of replacing *Helicobacter pylori*, the acknowledged cause for the development of ulcer, in the preparation of a support intended for the therapeutic or prophylactic treatment of an ulcer associated with the action of *Helicobacter pylori*.

In knowledge of the valuable properties particular strains of lactic acid bacteria may provide there is a desire in the art for additional lactic acid bacterial strains that are beneficial to the well being of man and/or animal.

Consequently, a problem of the present invention is to provide additional bacterial strains that exhibit new properties beneficial for man and/or animals.

The above problem has been solved by providing novel microorganisms, namely lactic acid bacteria, belonging to the genus *Lactobacillus* having the traits of being capable to adhere to and essentially colonize the intestinal mucosa and to prevent infection of intestinal epithelial cells by rotaviruses.

According to a preferred embodiment the *Lactobacillus* strains are capable to grow in the presence of up to 0.4 % bile salts, so that they may easily pass the gastrointestinal tract and stay essentially active.

According to another preferred embodiment the lactic acid bacterium is selected from the group consisting of *Lactobacillus rhamnosus* or *Lactobacillus paracasei*, preferably *Lactobacillus paracasei*, and is more preferably *Lactobacillus paracasei* CNCM I-2116.

The microorganisms of the present invention have been shown to exhibit the following properties, they are gram positive, catalase negative, NH_3 from arginine negative and CO_2 production negative. They produce L(+) lactic acid, are capable to

- 4 -

grow in the presence of bile salts in a concentration of up to about 0.4 % and may essentially prevent infection of epithelial cells by rotaviruses.

The novel microorganisms may be used for the preparation of a variety of ingestible support materials, such as e.g. milk, yogurt, curd, fermented milks, milk based ~~fermented products, fermented cereal based products, milk based powders, infant~~ formulae and may be included in the support in an amount of from about 10^5 cfu / g to about 10^{11} cfu / g. For the purpose of the present invention the abbreviation cfu shall designate a "colony forming unit" that is defined as number of bacterial cells as revealed by microbiological counts on agar plates.

The present invention also provides a food or a pharmaceutical composition containing at least one of the Lactobacillus strains having the above traits.

For preparing a food composition according to the present invention at least one of the Lactobacillus strains according to the present invention is incorporated in a suitable support, in an amount of from about 10^5 cfu / g to about 10^{11} cfu / g, preferably from about 10^6 cfu / g to about 10^{10} cfu / g, more preferably from about 10^7 cfu / g to about 10^9 cfu / g.

In case of a pharmaceutical preparation the product may be prepared in forms of tablets, liquid bacterial suspensions, dried oral supplements, wet oral supplements, dry tube feeding or a wet tube feeding etc., with the amount of Lactobacillus strains to be incorporated therein being in the range of up to 10^{12} cfu / g, preferably from about 10^7 cfu / g to about 10^{11} cfu / g, more preferably from about 10^7 cfu / g to about 10^{10} cfu / g .

The activity of the novel microorganisms in the individual's intestine is naturally dose dependent. That is, the more the novel microorganisms are incorporated by means of ingesting the above food material or the pharmaceutical composition the higher the

- 5 -

protective and/or curing activity of the microorganisms. Since the novel microorganisms are not detrimental to mankind and animals and have eventually been isolated from baby feces a high amount thereof may be incorporated so that essentially a high proportion of the individual's intestine will be colonized by the novel microorganisms.

In the figures,

Fig. 1 shows a scheme illustrating the cell culture screening for assessing rotaviral protective properties of bacterial strains.

Fig. 2 shows the acidification of the *L. casei* strain CNCM I-2116 (termed ST11) in different growth media.

Fig. 3 shows the survival rate of the *L. casei* strain ST11 at 10 °C measured during 30 days.

Fig. 4 shows the mRNA pattern of IL-12 and IL-10 in mouse adherent cells derived from bone marrow after incubation of the cells with serial dilutions of ST11.

Fig. 5 shows the outcome of Th2 differentiation as resulting in decreased IL-4 production.

During the extensive studies leading to the present invention the inventors have investigated baby feces and isolated a variety of different bacterial strains therefrom. These strains were subsequently examined for their capability to prevent infection of epithelial cells with rotaviruses that are known to cause diarrhea.

Several bacterial genera comprising *Lactobacillus*, *Lactococcus*, *Streptococcus* were screened for their rotavirus inhibitory properties. The tests for the inhibitory property

- 6 -

were essentially performed with three rotavirus serotypes representing the major etiological agents of human viral diarrhea (serotypes G1, G3 and G4).

The various lactic acid bacteria were grown in a suitable medium, such as MRS, Hugo-Jago or M17 medium at temperatures of from about 30 to 40°C corresponding to their optimal growth temperature. After reaching stationary growth the bacteria were collected by centrifugation and resuspended in physiological NaCl solution. Between the different tests the bacterial cells were stored frozen (-20°C).

The various rotavirus stocks were prepared by infection of confluent cell monolayers. The rotaviruses were incubated before infection. The cells were infected with 20 tissue culture infectious doses.

For assessing anti-rotaviral properties two different protocols were applied. According to one protocol the various bacterial strains were examined for their direct interaction with the rotavirus while in the second protocol the bacteria were screened for those strains that interact with cellular rotavirus receptors.

The first protocol involved contacting the respective bacterial suspension each with a different rotavirus strain and incubating in suitable media. Subsequently, the virus-bacterium mixture was applied to a monolayer of cells of the human undifferentiated colon adenoma cells HT-29 and incubation was continued. Virus replication was then assayed.

The second protocol involved incubating the respective bacterial suspension first together with a monolayer of cells of the human undifferentiated colon adenoma cells HT-29 and adding the virus subsequently. After continued incubation virus replication was assayed.

- 7 -

Rotavirus replication may easily be assessed by histo-immunological staining of rotavirus proteins in infected cells.

A rotavirus inhibitory effect was attributed to a given bacterium when the number of infected cells was reduced by 90% in the cell culture inoculated with rotavirus plus the indicated bacteria in comparison with cells inoculated only with rotavirus.

Out of a total of 260 different bacterial strains primarily isolated merely 9 could be shown to essentially inhibit rotaviral replication. The different bacteria were ascertained to belong to the genus *Lactobacillus* subspecies *ramnosus* or *paracasei*. One strain, termed *Lactobacillus casei* ST11, that has been deposited in accordance with the Budapest Treaty and has received the deposit numbers NCC 2461 (I-2116), has been shown to be extremely effective in preventing infection of human cells by rotavirus. Moreover, this particular strain shows excellent growing properties as may be shown by acidification in different media. The strain also shows good performance as regards the survival rate during storage at low temperatures of about 10 °C, which makes it an excellent candidate for being included in food stuff or pharmaceutical compositions to be stored at refrigerator conditions.

In addition to the above finding it could also be shown that the strains surprisingly also exhibit anti-allergenic properties in that said strains have an impact on the synthesis of different immunological mediators.

It is generally acknowledged that humoral immune responses and allergic reactions are mediated by CD4⁺ T cells bearing the type 2 phenotype (Th2). Th2-cells are characterized by the production of high levels of interleukin 4 (IL-4), a cytokine required for the secretion of IgE, which is the major antibody class involved in allergic reactions.

- 8 -

The differentiation of Th2 cells is impaired by IFN- γ , a particular cytokine that arises from the mutually exclusive Th1 subset of CD4⁺ T cells. Said Th1 cells are in turn strongly induced by interleukin 12 (IL-12). In contrast thereto IL-10, another cytokine, has been shown to have a strong suppressing impact on the proliferation of Th1 cells and is therefore deemed to play a role in immunosuppressive mechanisms.

In summary, both IL-12 and IL-10 have strong modulatory effects on CD4⁺ T cell development by influencing the development of the Th1 subset. IL-12 is a key regulatory cytokine for the induction of Th1 differentiation and thus inhibits the generation of Th2 responses. A major pathway for inhibition of Th2 cells is therefore seen in the stimulation of IL-12 synthesis by accessory cells.

It is well known that some components of gram negative bacteria, such as LPS, induce high levels of IL-12 in adherent cells, such as macrophages and dendritic cells. Consistently, it has been found that gram negative bacteria can strongly bias CD4⁺ T cell differentiation towards the Th1 phenotype.

The microorganism ST11 as an example of the Lactobacillus strains of the present invention has been tested for a potential role in the induction of cytokines involved in the regulation of CD4⁺ T cell differentiation. In particular, the effect of ST11 on the phenotype of CD4⁺ T cells undergoing Th2 differentiation has been studied.

In this respect the capacity of ST11 to induce the synthesis of mRNA encoding these two regulatory cytokines in mouse adherent cells derived from bone marrow was compared with 4 other strains of Lactobacilli and with a control of gram negative bacteria (E.coli K12). The mRNA was measured by semi-quantitative RT-PCR after 6 hours of incubation of the cells with serial dilutions of bacteria ranging from 10⁹ to 10⁷ cfu/ml.

- 9 -

Although all strains of *Lactobacillus* could induce transcription of IL-12 mRNA to a certain degree, ST11 could be shown to be the strongest inducer, since as a strong PCR signal could be detected even at the lowest bacterial dose. In fact, the capacity of ST11 to induce IL-12 mRNA transcription was as strong as that of *E. coli*. Induction of IL-10 mRNA was in general weaker than for IL-12 mRNA, as only at ~~higher bacterial doses a signal could be detected~~. Nevertheless, ST11 was the strongest inducer of IL-10 mRNA, as compared to the other lactobactilli and the *E. coli* control.

Thus, ST11 is deemed to be efficient in inducing immunoregulatory cytokines involved in CD4⁺ T cell differentiation. Its strong capacity to induce IL-12 makes it a candidate to inhibit Th2 responses and its measurable IL-10 induction may prevent inflammatory responses.

In addition to the above finding it was also determined whether ST11 had an inhibitory effect on CD4⁺ T cells undergoing Th2 differentiation and a positive effect on Th1 functions. A well established cell differentiation culture system was utilized, where precursor CD4⁺ T cells were polyclonally activated and modulated to undergo either Th1 or Th2 differentiation, depending on the type of co-stimuli provided in the culture medium. Th1/Th2 differentiation was induced during a 7-days primary culture, after which the cells were then restimulated for 2 days in a secondary culture containing medium alone and acquisition of a specific phenotype (Th1 or Th2) was assessed by measuring the types of cytokines produced in the supernatant (IFN- γ vs. IL-4).

It is known that precursor CD4⁺ T cells from mice of the BALB/c background preferentially differentiate to predominant Th2 phenotype (high IL-4, low IFN- γ in the 2ry culture supernatants) after activation under neutral conditions (medium alone in the 1ry culture). This phenotype could be completely reverted to a Th1 pattern

- 10 -

(high IFN- γ , low IL-4) upon addition of a blocking monoclonal antibody to IL-4 in the 1ry culture.

To investigate a potential role for ST11 on Th2 inhibition, purified precursor CD4⁺ T cells from BALB/c mice were activated in the presence of bone marrow adherent cells as accessory cells during the 1ry culture. These cells were co-cultured either in medium alone, or in the presence of 1 mg/ml LPS, or 10⁸ cfu/ml ST11, or 10⁸ cfu/ml of another Lactobacillus. After this time, the cells were washed and CD4⁺ T cells were purified once again and restimulated in the 2ry culture in medium alone. Cytokines produced by the differentiated CD4⁺ T cells were measured after 2 days. As expected, cells differentiated in the presence of medium alone displayed a dominant Th2 phenotype. Addition of ST11 to the 1ry cultures strongly modulated the outcome of Th2 differentiation, as it resulted in an 8-fold decrease in IL-4 production. This inhibition was of similar magnitude as that observed in cultures derived from cells differentiated in the presence of LPS. In contrast, the other Lactobacillus strain had no measurable impact on IL-4 levels. Interestingly, IFN- γ levels were not increased upon addition of ST11 in the 1ry cultures.

In summary, ST11 specifically impaired IL-4 production by CD4⁺ T cells undergoing Th2 differentiation, but did not significantly increase IFN- γ secretion. The fact that ST11 does not increase IFN- γ production may be due to its capacity to induce IL-10 with the consequence that it may keep a low inflammatory impact despite its anti-Th2 activity.

In consequence, it could be shown that ST11 is a Lactobacillus strain that has a good anti-Th2 profile which makes it an excellent candidate for its use as a bacterium with anti-allergic, probiotic activity.

The present invention will now be described by way of example.

- 11 -

Media and solutions:

MRS (Difco),

Hugo-Jago (Tryptone Difco 30 g/l, Yeast Extract Difco 10 g/l, Lactose Difco 5 g/l, KH_2PO_4 5 g/l, Beef Extract Difco 2 g/l, agar Difco 2 g/l)

M17 (Difco)

M199 (Seromed)

Ringer solution (Oxoid)

PBS (NaCl 8g/l, KCl 0.2 g/l, Na_2HPO_4 1.15 g/l, KH_2PO_4 0.2 g/l)

Tryptose phosphate broth (Flow)

Trypsin-EDTA solution (Seromed)

Human rotavirus Wa (G1 serotype) and simian rotavirus SA-11 (G3 serotype) were obtained from P.A. Offit, Children's Hospital of Philadelphia, U.S.A. The DS-1xRRV reassortant virus was obtained from A. Kapikian, NIH Bethesda, U.S.A. The serotype 4 human rotavirus Hocht was obtained from P. Bachmann, University of Munich, Germany.

Example 1

Isolation of lactic acid bacteria from baby feces

Fresh feces were harvested from diapers of 16 healthy babies 15 to 27 days old. 1 g of fresh feces was placed under anaerobic conditions for transportation to the laboratory and microbiological analyses were run within 2 hours from sampling by serial dilutions in Ringer solution and plating on selective media. MRS agar plus antibiotics (phosphomycin 80 $\mu\text{g/ml}$, sulfamethoxazole 93 $\mu\text{g/ml}$, trimethoprim 5 $\mu\text{g/ml}$) incubated at 37°C for 48 hours was used to isolate lactic acid bacteria. Colonies were randomly picked up and purified. Physiological and genetic characterisation was performed on the isolates.

Example 2

Testing of strains in cell culture for anti-rotaviral activity

Several bacterial genera comprising *Lactobacillus*, *Lactococcus*, *Streptococcus* were selected and tested for members which showed anti-rotavirus activity in the cell culture inhibition test. The genus *Lactococcus* was represented by a single species (*Lc. lactis*) consisting of two subspecies (*Lc. lactis* supsp. *lactis* and *cremoris*). A total of 30 strains were tested. The *Streptococcus* genus was represented by a single species (*S. thermophilus*) with 45 strains. The *Leuconostoc* and *Propionibacterium* genus were only represented by a single species (6 strains), while the *Enterococcus* and *Staphylococcus* genus was represented by two species each and a total of 17 strains.

In total, 260 bacterial strains were tested for rotavirus inhibitory activity.

1st protocol:

30 µl of bacterial suspension (containing at average 3×10^6 bacteria) were mixed with 70 µl M199 medium supplemented with 10% tryptose phosphate broth (Flow) and 5% trypsin-EDTA solution (Seromed) (1 : 4 diluted in the case of HT-29 cells) and 100 µl of virus in supplemented M199 medium. The virus-bacterium mixture was incubated for 1 hour at 4°C and for 1 hour at 37°C. Cells of the human undifferentiated colon adenoma cells HT-29 growing as a confluent monolayer in 96-well microtiter plates were washed three times with phosphate-buffered saline (PBS ; pH 7.2). The virus-bacterium mixture was applied to the cells and the microtiter plates were incubated for 18 h in a CO₂ incubator (Heraeus). Virus replication was assayed as described below.

2nd protocol:

30 µl of the bacterial suspension (supra) were mixed with 70 µl M199 medium supplemented with 10% tryptose phosphate broth (Flow) and 5% trypsin-EDTA

- 13 -

solution (Seromed) (1 : 4 diluted in the case of HT-29 cells) and applied directly on the cells in the microtiter plates. After one hour incubation at 37°C 100 µl of virus in supplemented M199 medium was added to the cells in the microtiter plates. The incubation was continued for 18 h in a CO₂ incubator (Heraeus). Virus replication was assayed as described below.

The rotavirus replication was assessed by histo-immunological staining of rotavirus proteins in infected cells as described hereafter.

One day after infection, the cell culture medium was discarded from the microtiter plates and the cells were fixed with absolute ethanol for 10 min. Ethanol was discarded, and the plates were washed three times in PBS buffer. Then 50 µl of an anti-rotavirus serum (mainly directed against VP6 protein), produced in rabbits (obtained from the ISREC University of Lausanne) and diluted 1 :2000 in PBS was added to each well and incubated for 1 h at 37°C with a cover slip to prevent desiccation of the wells. The antiserum was discarded afterwards and the plates were washed three times with PBS. Then 50 µl of anti-rabbit immunoglobulin G (IgG) antiserum produced in goats and coupled to peroxidase (GAR-IgG-PO; Nordic) were added at a dilution of 1 : 500 in PBS to each well and the plates were incubated for 1 hour at 37 °C. The serum was discarded and the plates were once again washed three times with PBS. Then 100 µl of the following substrate mixture was added to each well : 10 ml of 0.05 M Tris-hydrochloride (pH 7.8), 1 ml of H₂O₂ (30% suprapur, diluted 1 :600 in H₂O ; Merck) and 200 µl of 3-amino-9-ethylcarbazole (0.1 g/10 ml of ethanol stored in 200 µl aliquots at -80 °C ; A-5754 ; Sigma). The plates were incubated for at least 30 min at room temperature. The substrate was discarded and the wells were filled with 200 µl of H₂O to stop the reaction. Infected cell foci were counted with an inverted microscope (Diavert ; Leitz).

Only very few bacterial strains interacted with rotaviruses. Merely 9 out of the 260 bacterial cells primarily selected inhibited rotavirus replication in at least one

- 14 -

protocol. *Lactobacillus paracasei* NCC 2461 (ST11) showed an extremely high activity against Serotype 1 Rotavirus, Serotype 3 rotavirus SA-11 and Serotype 4 rotavirus Hocht.

Example 3

Properties of ST11

ST 11 has been subjected to incubation in simulated gastric juice. The simulated gastric juice was prepared by suspending pepsin (3 g/l) in sterile saline (0.5% w/v) and adjusting the pH to 2.0 and pH 3, respectively, with concentrated HCl. ST 11 has been grown in varying amounts in the above media and the resistance of the microorganisms has been determined.

The results are summarized in table I below . .

Table I

pH	cfu/ml at T 0	cfu at T 1min	Cfu at T 15	cfu at T 30	cfu at T 60
2.0	2.0×10^9	1.8×10^9	1.2×10^9	3.7×10^8	7.0×10^3
3.0	2.0×10^9	1.9×10^9	1.7×10^9	1.7×10^9	8.4×10^8

ST11 has the following properties as defined according to methods disclosed in the genera of lactic acid bacteria, Ed. B.J.B. Wood and W.H. Holzapfel, Blackie A&P.

- gram positive,
- catalase negative,
- NH_3 form arginine negative
- CO_2 production negative
- production of L(+) lactic acid
- growth in the presence of bile salts in a concentration of up to about 0.4 %.

- 15 -

Example 4**Growth of ST 11 under different conditions**

ST11 was incubated at 37 °C in tomato based medium (4% tomato powder rehydrated in distilled water) supplemented with sucrose (0, 0.5, 1 or 2%) or soya peptone (0.5%) or glucose (0.5%) for different periods of time. The results are shown in fig. 2.

ST11 was further added in an amount of 2.5 % to a medium composed of rice flour (3%), wheat flour (2%) and sucrose (3%) and incubated at 37°C until a pH of 4.4 was reached. After cooling the product was packed with or without addition of vit.C and stored at 10°C.

Example 5**Induction of IL-12 and IL10- mRNA synthesis in mouse adherent cells by ST11**

Bone marrow cells were isolated from the femur and tibia of 8 week-old specific pathogen-free C57BL/6 mice and were incubated at a concentration of 2×10^6 cells/ml in RPMI medium (Gibco) containing 10% fetal bovine serum, 1 mM L-Glutamine, 12 mM Hepes, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin (all reagents from Gibco) for 12 hours at 37°C in a 5% CO₂ atmosphere. Non-adherent cells were discarded by 3 consecutive washes with warm culture medium and the remaining adherent cells were harvested and incubated at a concentration of 10^6 cells/ml for 6 hours in the presence or absence of bacteria. It was previously determined that 6 hours represents an optimal time-point for cytokine mRNA synthesis by mouse adherent cells in response to LPS. Bacteria were added at different concentrations ranging from 10^9 to 10^7 cfu/ml. Bacteria were grown and stored as indicated above (page 6).

- 16 -

At the end of the 6-hour culture period, cells were isolated by centrifugation and lysed using the TRIzol reagent kit (GibcoBRL, Cat. No. 15596-018) following the manufacturer's instructions. Total RNA was isolated by isopropanol precipitation and reverse-transcribed into cDNA for 90 min at 42°C using 200 U reverse transcriptase (Superscript II, BRL) in a 40- μ l reaction volume containing 200 mM Tris pH 8.3, 25 mM KCl, 1 μ g/ml oligo d(T)₁₈ (Boehringer Mannheim), 1 mM DTT (Boehringer Mannheim), 4 mM of each dNTP (Boehringer Mannheim) and 40 U/ml Rnasin (Promega). PCR primers and conditions were used as already described in Kopf et al. (Journal of Experimental Medicine 1996 Sep 1;184(3):1127-36). Amounts of cDNA were normalized within the samples using primers specific for a house-keeping gene (β -2-microglobulin). PCR products were separated on a 2% agarose gel and bands were analyzed under UV.

As shown in Figure 4, ST11 showed the strongest induction of IL-12 and IL-10 mRNA, which was comparable to levels observed with the positive control (*E. coli*). Differences are best seen at the lowest bacteria concentrations (10^7 cfu/ml).

Example 6

Suppression of IL-4 synthesis by ST11

CD4⁺ T cells were purified from the spleen of specific pathogen-free BALB/c mice using the MiniMACS kit from Miltenyi Biotec (Cat. No. 492-01). The CD4⁺ T cells were cultured at a concentration of 2×10^5 cells/ml in RPMI medium containing 10% fetal bovine serum, 1 mM L-Glutamine, 12 mM Hepes, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin and 100 μ g/ml streptomycin and activated during one week by cross-linking with plate-bound monoclonal antibodies to CD3 (clone 2C11) and CD28 (clone 37.51, both antibodies from Pharmingen). During this 1ry culture, the CD4⁺ T cells were co-cultured with bone marrow adherent cells (isolated as described above) as accessory cells and with 10^8 cfu/ml ST11, or 10^8 cfu/ml La1, or 1 mg/ml LPS, or medium alone. After this time, the cells were washed and CD4⁺ T cells were

- 17 -

purified once again using MiniMACS kit technology and restimulated in a 2ry culture containing medium alone. Cytokines produced by the differentiated CD4⁺ T cells were measured in the supernatants after 2 days using sandwich ELISA (kits from Endogen and Pharmingen).

~~Results are shown in Fig. 5. Cells differentiated in the presence of medium alone~~ displayed a dominant Th2 phenotype characterized by high levels of IL-4. Addition of ST11 to the 1ry cultures strongly modulated the outcome of Th2 differentiation, as it resulted in an 8-fold decrease in IL-4 production. This inhibition was of similar magnitude as that observed in cultures derived from cells differentiated in the presence of LPS. In contrast thereto, the other Lactobacillus strain had no measurable impact on IL-4 levels. Interestingly, IFN- γ levels were not increased upon addition of ST11 in the 1ry cultures.

As may be seen from the above the strains of the present invention may be well prepared for the production of a food and/or a pharmaceutical carrier taking advantage of the valuable properties of the microorganisms.

Claims

1. Lactic acid bacterium belonging to the genus *Lactobacillus* capable of adhering to and essentially colonizing the intestinal mucosa and capable of preventing infection ~~of intestinal epithelial cells by rotaviruses.~~
2. The *Lactobacillus* according to claim 1, which is capable to grow in the presence of up to 0.4 % bile salts.
3. The *Lactobacillus* according to claim 1 or claim 2, which is selected from the group consisting of *Lactobacillus rhamnosus* or *Lactobacillus paracasei*.
4. The *Lactobacillus* according to claim 3, which is *Lactobacillus paracasei*.
5. The *Lactobacillus paracasei* strain according to claim 4, which is *Lactobacillus paracasei* CNCM I-2116.
6. Use of a lactic acid bacterium according to any of the preceding claims for the preparation of a ingestable support material.
7. The use according to claim 6, wherein the *Lactobacillus* strain is contained in the support material in an amount from about 10^5 cfu / g to about 10^{12} cfu / g support material.
8. The use according to any of the claims 6 or 7, wherein the support material is a food composition selected from milk, yogurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae.

- 19 -


9. The use according to any of the claims 5 to 7, wherein the support material is used for the treatment and/or prophylaxis of disorders associated with diarrhea.
10. Food or pharmaceutical composition containing at least one lactic acid bacterium according to any of the claims 1 to 4.
-
11. The composition according to claim 10, which is selected from milk, yogurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae, tablets, liquid bacterial suspensions, dried oral supplement, wet oral supplement, dry tube feeding or wet tubefeeding.

EPO - Munich
32

1. März 1999

Fig. 1

Cell Culture Screening





Acidification of *L. casei* ST11 in different growth media

Fig. 2

Survival in cereal drink

Survival of *Lb. Casei* ST11

at 10 °C



Vit C: vitamin C

PS: polystyrene

HDPE: High density poly ethilene

Fig. 3

Fig. 4

INDUCTION OF CYTOKINE mRNA BY LAB IN MOUSE MACROPHAGES





Fig. 5

CYTOKINE RELEASE IN IVD 980916
(ELISA 981103 & 980925)



11

12

13

- 20 -

EPO - Munich
32
11. März 1999Summary

The present invention pertains to novel microorganisms of the family Lactobacillaceae, especially to microorganisms of the genus Lactobacillus, that are ~~useful in preventing or treating diarrhea. In particular, the present invention relates to~~ the use of said micro-organisms for the preparation of an ingestible support and to a composition containing the same.
